Research progress of new tumor imaging agent 68Ga-FAPIs
10.3760/cma.j.cn321828-20200313-00100
- VernacularTitle:肿瘤新型显像剂 68Ga-FAPIs的研究进展
- Author:
Jingyi WANG
;
Weidong YANG
;
Jing WANG
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2021;41(6):374-377
- CountryChina
- Language:Chinese
-
Abstract:
18F-fluorodeoxyglucose (FDG) is the most commonly used broad-spectrum tumor imaging agent, but there are certain limitations in the application of some tumors. Fibroblast activation protein (FAP) is selectively expressed in more than 90% of malignant epithelial tumors, while it is hardly expressed in normal tissues and benign tumors. FAP inhibitors (FAPIs) specifically bind to FAP and selectively target FAP-positive tissues. In recent years, it has been reported that radionuclide-labeled FAPIs, such as 68Ga-FAPIs, are safe and reliable in tumor imaging and have low tissue background. They can also be used to image a variety of solid tumors, which are expected to be new tumor broad-spectrum imaging agents and play a greater role in clinical applications. This article reviews the recent progress of FAPIs in tumor imaging and diagnosis at home and abroad.
